ReviewFrontiers in neurology2021
Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review.
Review in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Measuring Fatigue in Multiple Sclerosis: A Rapid Review.The patient · 2025Pooled it
- Effect of Vitamin D Supplementation on Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Nutrients · 2023Pooled it
- The locus coeruleus at the crossroads of inflammation and neurodegeneration in multiple sclerosis.Journal of neuroinflammation · 2026Review
- Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis.Journal of neurology · 2026Article
- Cerebrospinal fluid glucose levels and their association with disability, depression, and cognitive function in multiple sclerosis.Metabolic brain disease · 2026Article
- Linking movement-related beta oscillations to cortical excitability, structural damage, and fatigue in multiple sclerosis.Brain communications · 2026Article
- Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis.Brain communications · 2026Article
- Reduced peripheral serotonin levels in women with multiple sclerosis: associations with underweight status, treatment duration, and use of interferon beta 1a.Frontiers in cellular neuroscience · 2026Article
- Multidimensional Impairment in Multiple Sclerosis: Physical Disability, Cognitive Dysfunction, Sleep Disturbance, Fatigue, Depression, and Their Impact on Quality of Life-A Possible Common Pathological Pathway.Neurology international · 2025Article
- Distinguishing Mental From Physical Fatigue in Patients With Low-Grade Glioma.Psycho-oncology · 2025Article
- The protective role of cognitive reserve in moderating depressive symptomatology in patients with multiple sclerosis.BMC psychology · 2025Article
- Clinical and paraclinical features distinguish fatigue from depression-predominant phenotypes in multiple sclerosis.Scientific reports · 2025Observational
- Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.Journal of neurology · 2025Article
- Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis.European journal of neurology · 2025Article
- The Impact of Urodynamic Findings on Fatigue and Depression in People with Multiple Sclerosis.Biomedicines · 2025Article
- Application of machine learning in depression risk prediction for connective tissue diseases.Scientific reports · 2025Article
- Behavioral disorders in multiple sclerosis: a comprehensive review.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Factors affecting fatigue progression in multiple sclerosis patients.Scientific reports · 2024Article
- Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Stressful life events and depression and fatigue in people with multiple sclerosis: a cross-sectional analysis of an international cohort.Acta neurologica Belgica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue and depression are common conditions diagnosed in people with multiple sclerosis (MS). Fatigue defined as subjective lack of physical and/or mental energy is present in 35-97% of people with MS, who classify it as one of the most serious symptoms interfering with daily activities and influencing the quality of life. Depression is diagnosed in about 50% of people with MS. Since fatigue and depression frequently coexists, it may be quite hard to differentiate them. Primary fatigue and primary depression in MS are caused by inflammatory, oxidative/nitrosative, and neurodegenerative processes leading to demyelination, axonal damage, and brain atrophy. In people with MS and comorbid fatigue and/or depression there is reported increased serum and cerebrospinal fluid concentration of inflammatory mediators such as tumor necrosis factor, interleukins (IL-1a, IL-1b, IL-6), interferon γ and neopterin. Moreover, the brain atrophy of prefrontal, frontal, parietotemporal regions, thalamus, and basal ganglia was observed in people with MS with fatigue and/or depression. The secondary fatigue and secondary depression in people with MS may be caused by emotional factors, sleep disorders, pain, the coexistence of other diseases, and the use of medications. In some studies, the use of disease-modifying therapies positively influenced fatigue, probably by reducing the inflammatory response, which proves that fatigue and depression are closely related to immunological factors. In this mini-review, the pathogenesis, methods of evaluation and differentiation, and possible therapies for fatigue and depression in MS are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.